Loading…

The PD-1/PD-Ls pathway and autoimmune diseases

•We give a review about the soluble forms of PD-1/PD-Ls pathway.•We give a summary figure about the function of sPD-1.•We give a summary figure about the role of PD-1/PD-Ls pathway in T1DM. The programmed death (PD)-1/PD-1 ligands (PD-Ls) pathway, is a new member of the B7/CD28 family, and consists...

Full description

Saved in:
Bibliographic Details
Published in:Cellular immunology 2014-07, Vol.290 (1), p.72-79
Main Authors: Dai, Suya, Jia, Ru, Zhang, Xiao, Fang, Qiwen, Huang, Lijuan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•We give a review about the soluble forms of PD-1/PD-Ls pathway.•We give a summary figure about the function of sPD-1.•We give a summary figure about the role of PD-1/PD-Ls pathway in T1DM. The programmed death (PD)-1/PD-1 ligands (PD-Ls) pathway, is a new member of the B7/CD28 family, and consists of the PD-1 receptor and its ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273). Recently, it is reported that PD-1, PD-L1 and PD-L2 also have soluble forms aside from their membrane bound forms. The soluble forms increase the diversity and complexity of PD-1/PD-Ls pathway in both composition and function. The PD-1/PD-Ls pathway is broadly expressed and exerts a wider range of immunoregulatory roles in T-cell activation and tolerance compared with other B7/CD28 family members. Studies show that the PD-1/PD-Ls pathway regulates the induction and maintenance of peripheral tolerance and protects tissues from autoimmune attack in physiological conditions. In addition, it is also involved in various diseases mediated by T cells, such as autoimmunity, tumor immunity, chronic viral infections, and transplantation immunity. In this review, we will summarize the relevance of the soluble forms and the latest researches on the role of PD-1/PD-Ls pathway in autoimmune diseases.
ISSN:0008-8749
1090-2163
DOI:10.1016/j.cellimm.2014.05.006